Follow-up Study to Evaluate the Long-term Efficacy of a HPV Vaccine (580299) in Healthy Young Adult Women in Brazil
In this extension study, women who were vaccinated in the primary study, and participated in
the follow-up study, will be followed for a further 3 years with visits every 6 months.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Number of Subjects Presenting Cervical Infections With Human Papillomavirus (HPV) -16 and/or HPV-18
Cervical HPV infection was defined as the first detection of an HPV type in a subject previously negative for that HPV type.
Up to year 8
No
GSK Clinical Trials
Study Director
GlaxoSmithKline
Brazil: ANVISA
109616 (Y7)
NCT00518336
November 2007
September 2010
Name | Location |
---|